← Back to Search

T cell Therapy

Posoleucel (ALVR105) for Progressive Multifocal Leukoencephalopathy (Prevent Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by AlloVir
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Use of umbilical cord blood as stem cell source
Key Inclusion Criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through weeks 14 and 26
Awards & highlights

Prevent Trial Summary

This trial will test an allogeneic, off-the-shelf multi-virus specific T cell therapy (posoleucel) that targets six viral pathogens.

Eligible Conditions
  • HHV-6 Infection
  • Progressive Multifocal Leukoencephalopathy
  • EBV Infection
  • BK Virus Infection
  • Cytomegalovirus
  • Adenovirus Infections

Prevent Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Prevent Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through weeks 14 and 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and through weeks 14 and 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Incidence of Adverse Events
Mean area under the curve (AUC) viral load
Number of clinically significant infections or episodes of end-organ disease
+2 more

Prevent Trial Design

1Treatment groups
Experimental Treatment
Group I: Posoleucel (ALVR105)Experimental Treatment1 Intervention
Administered as 2-4 milliliter infusion

Find a Location

Who is running the clinical trial?

AlloVirLead Sponsor
11 Previous Clinical Trials
720 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please tell me how many different hospitals are a part of this research project?

"Thirteen locations are running this study, some notable ones being University of Kansas Hospital in Westwood, Stony Brook University Hospital Cancer Center in Stony Brook, and Indiana University Melvin and Bren Simon Cancer Center in Indianapolis."

Answered by AI

Are there additional examples of research using Viralym-M Cells?

"University of Maryland Medical Center first began studying Viralym-M cells in 2021. As of now, there has only been 0 completed trials. However, 1 clinical trial is still ongoing with many studies being conducted in Westwood, Kansas."

Answered by AI

How many people are participating in this clinical trial?

"This study is not looking for volunteers at the moment. However, it's worth noting that the clinical trial was first posted on 1/15/2021 and last updated on 5/2/2022. If you're interested in other studies, 924 trials involving cytomegalovirus infections are actively recruiting patients right now and 1 Viralym-M Cells trial is also admitting patients."

Answered by AI

Are volunteers still needed for this experiment?

"Unfortunately, this study is not admitting patients at the moment. Although, it's worth noting that the study was first posted on 1/15/2021 and edited as recently as 5/2/2022. If you're still interested in participating in trials, there are 924 other studies currently recruiting for patients with cytomegalovirus infections and 1 trial for Viralym-M cells."

Answered by AI

Is this the first time this type of experiment has been conducted?

"There is only one ongoing clinical trial for Viralym-M Cells in 13 cities and 1 country. The first ever study was conducted in 2021 by AlloVir. That particular research project, which reached Phases 2 & 3, had a total of 35 participants. Since that time, no other trials have been attempted."

Answered by AI
Recent research and studies
~8 spots leftby Mar 2025